HPV vaccines: Translating immunogenicity into efficacy

References

• Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004; 4:46-54; PMID:14704767; http://dx.doi.org/10.1038/nri1260
   PubMed Web of Science ®Google Scholar
• Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181:1911-9; PMID:10837170; http://dx.doi.org/10.1086/315498
   PubMed Web of Science ®Google Scholar
• Jochmus-Kudielka I, Schneider A, Braun R, Kimmig R, Koldovsky U, Schneweis KE, Seedorf K, Gissmann L. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 1989; 81:1698-704; PMID:2553991; http://dx.doi.org/10.1093/jnci/81.22.1698
   PubMed Web of Science ®Google Scholar
• Fairley CK, Chen S, Tabrizi SN, McNeil J, Becker G, Walker R, Atkins RC, Thomson N, Allan P, Woodburn C, et al. Prevalence of HPV DNA in cervical specimens in women with renal transplants: A comparison with dialysis-dependent patients and patients with renal impairment. Nephrol Dial Transplantat 1994; 9:416-20; PMID: 8084456
   PubMed Web of Science ®Google Scholar
• Leigh IM, Glover MT. Skin cancer and warts in immunosuppressed renal transplant recipients. Recent Results Cancer Res 1995; 139:69-86; PMID:7597313
   PubMedGoogle Scholar
• Özsaran AA, Ateş T, Dikmen Y, Zeytinoglu A, Terek C, Erhan Y, Özacar T, Bilgiç A. Evaluation of the risk of cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant patients receiving immunosuppressive therapy. Eur J Gynaecol Oncol 1999; 20:127-30
   PubMed Web of Science ®Google Scholar
• Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001; 8:209-20; PMID:11238198
   PubMedGoogle Scholar
• Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, Zahaf T, Catteau G, Geeraerts B, Descamps D. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother 2014; 10:2147-62; PMID:25424918; http://dx.doi.org/10.4161/hv.29532
   PubMed Web of Science ®Google Scholar
• Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374:1975-85; PMID:19962185; http://dx.doi.org/10.1016/S0140-6736(09)61567-1
   PubMed Web of Science ®Google Scholar
• Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, Sanchez N, Geeraerts B, Descamps D. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012; 8:390-7; PMID:22327492; http://dx.doi.org/10.4161/hv.18865
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Huang LM, Medina DM, Valencia A, Lin TY, Behre U, Catteau G, Thomas F, Descamps D. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years. J Adolesc Health 2012; 50:187-94; PMID:22265115; http://dx.doi.org/10.1016/j.jadohealth.2011.11.004
   PubMed Web of Science ®Google Scholar
• Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh- Desmarquet C, Orth G, Schiller JT, Lowy DR. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69:3959-63; PMID:7745754
   PubMed Web of Science ®Google Scholar
• Ghim SJ, Newsome J, Bell J, Sundberg JP, Schlegel R, Jenson AB. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus. Exp Mol Pathol 2000; 68:147-51; PMID:10816383; http://dx.doi.org/10.1006/exmp.1999.2298
   PubMed Web of Science ®Google Scholar
• Ho GYF, Studentsov Y, Hall CB, Bierman R, Beardsley L, Lempa M, Burk RD. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002; 186:737-42; PMID:12198606; http://dx.doi.org/10.1086/342972
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47:401-9; PMID:18558875; http://dx.doi.org/10.1086/589862
   PubMed Web of Science ®Google Scholar
• Onorato IM, Modlin JF, McBean AM, Thorns ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 1991; 163:1-6; PMID:1845806; http://dx.doi.org/10.1093/infdis/163.1.1
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Starr SE, Friedman HM, Gonczol E, Weibel RE. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 1989; 159:860-5; PMID:2540247; http://dx.doi.org/10.1093/infdis/159.5.860
   PubMed Web of Science ®Google Scholar
• Taranger J, Trollfors B, Lagergård T, Sundh V, Bryla DA, Schneerson R, Robbins JB. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 2000; 181:1010-3; PMID:10720524; http://dx.doi.org/10.1086/315318
   PubMed Web of Science ®Google Scholar
• Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA. Measles antibody: Reevaluation of protective titers. J Infect Dis 1990; 162:1036-42; PMID:2230231; http://dx.doi.org/10.1093/infdis/162.5.1036
   PubMed Web of Science ®Google Scholar
• Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI, et al. Correlates of immune protection induced by live, attenuated, cold- adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181:1133-7; PMID:10720541; http://dx.doi.org/10.1086/315323
   PubMed Web of Science ®Google Scholar
• Lowe RS, Brown DR, Bryan JT, Cook JC, George HA, Hofmann KJ, Hurni WM, Joyce JG, Dale Lehman E, Markus HZ, et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 1997; 176:1141-5; PMID:9359711; http://dx.doi.org/10.1086/514105
   PubMed Web of Science ®Google Scholar
• Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, De Grandi P. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003; 95:1128-37; PMID:12902442; http://dx.doi.org/10.1093/jnci/djg018
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17:1055-65; PMID:20463105; http://dx.doi.org/10.1128/CVI.00131-10
   PubMed Web of Science ®Google Scholar